On April 01, 2024: Otsuka and Click Therapeutics announced the FDA Clearance of Rejoyn™: the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms.

Watch this YouTube video, where Dr. Harvinder Singh has summarized Rejoyn in the following sections:
1. Indication
2. Product Description
3. Recommended Treatment Schedule
4. Alternate Treatment Schedule
5. Mechanism of Action
6. Clinical Trial Data: Mirai Trial
7. Adverse Events: Suicidality
8. How to Use/Prescribe?

Read our blog post here: https://psychiatryeducationforum.com/...